FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:923-925 March 26, 1998 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The use of mesalamine (5-aminosalicylic acid) for the treatment of inflammatory bowel disease seems paradoxical, since structurally similar acetylsalicylic acid and other nonsteroidal antiinflammatory drugs (NSAIDs) can cause or exacerbate intestinal inflammation and diarrhea through their effects on arachidonic acid metabolism.¹ We describe a patient with inflammatory bowel disease of the small bowel and colon who had large-volume diarrhea while fasting during treatment with mesalamine, which was associated with changes in fecal eicosanoid content that mimicked effects expected with the use of NSAIDs that relieve pain.

A 57-year-old man with a 10-month history of weight loss, abdominal . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.